Kayalvizhi Madhivanan

Title: Kayalvizhi Madhivanan: Innovator in RNAi Therapeutics

Introduction

Kayalvizhi Madhivanan is a prominent inventor based in San Diego, CA (US). She has made significant contributions to the field of RNA interference (RNAi) therapeutics. Her work focuses on innovative methods for inhibiting the expression of the microtubule-associated protein tau (MAPT), which is crucial in the study of neurodegenerative diseases.

Latest Patents

Madhivanan holds a patent for "RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use." This patent describes RNAi agents and compositions that include these agents, aimed at inhibiting the MAPT gene expression. The agents are designed to be conjugated with an antigen-binding protein, facilitating their delivery across the blood-brain barrier (BBB). This innovative approach has potential therapeutic benefits for treating various tauopathies, including Alzheimer's disease and Frontotemporal lobar degeneration dementia (FTLD).

Career Highlights

Kayalvizhi Madhivanan is currently associated with Arrowhead Pharmaceuticals, Inc., where she continues her research and development in RNAi technologies. Her work has been instrumental in advancing the understanding of MAPT gene inhibition and its implications for central nervous system (CNS) disorders.

Collaborations

Madhivanan collaborates with esteemed colleagues such as Ji Young Suk and Jingdong Ye. These partnerships enhance the research efforts and contribute to the innovative solutions being developed in the field of RNAi therapeutics.

Conclusion

Kayalvizhi Madhivanan's contributions to RNAi therapeutics represent a significant advancement in the treatment of neurodegenerative diseases. Her innovative approaches and collaborations continue to pave the way for future breakthroughs in this critical area of research.